The structural basis of antibody-antigen recognition

Frontiers in Immunology

Volumn 4, Issue OCT, 2013, Pages

  Sela Culang, Inbal ^a   Kunik, Vered ^a   Ofran, Yanay ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

Antibody; Antigen; CDRs; Constant domain; Epitope; Framework; Paratope

Indexed keywords

EPITOPE;

ANTIBODY COMBINING SITE; ANTIBODY ENGINEERING; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; COMPLEMENTARITY DETERMINING REGION; FRAMEWORK REGION RESIDUE; HUMAN; IMMUNOGLOBULIN CONSTANT REGION; IMMUNOGLOBULIN STRUCTURE; MOLECULAR MODEL; MOLECULAR RECOGNITION; VIRUS TRANSMISSION;

EID: 84885405356     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00302     Document Type: Article

References (155)

1. Vincent KJ, Zurini M. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. Biotechnol J (2012) 7:1444-50. doi:10.1002/biot.201200250.
2. Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J Pharm Sci (2007) 96:1-26. doi:10.1002/jps.20727.
3. Sheedy C, MacKenzie CR, Hall JC. Isolation and affinity maturation of hapten-specific antibodies. Biotechnol Adv (2007) 25:333-52. doi:10.1016/j.biotechadv.2007.02.003.
4. Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol (2007) 25:1369-72. doi:10.1038/nbt1207-1369.
5. Brusic V, Bajic VB, Petrovsky N. Computational methods for prediction of T-cell epitopes-a framework for modelling, testing, and applications. Methods (2004) 34:436-43. doi:10.1016/j.ymeth.2004.06.006.
6. Kim Y, Sette A, Peters B. Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource. J Immunol Methods (2011) 374:62-9. doi:10.1016/j.jim.2010.10.010.
7. Frank SA. Specificity and cross-reactivity (Chapter 4). In: Immunology and Evolution of Infectious Disease. Princeton, NJ: Princeton University Press (2002). p. 33-54.
8. Rose NR, MacKay IR, editors. T-cells and autoimmunity. In: The Autoimmune Diseases, 4th ed. San Diego: Elsevier Academic Press (2006). 1160 p.
9. Jones S, Thornton JM. Principles of protein-protein interactions. Proc Natl Acad Sci U S A (1996) 93:13-20. doi:10.1073/pnas.93.1.13.
10. Jones S, Thornton JM. Analysis of protein-protein interaction sites using surface patches. J Mol Biol (1997) 272:121-32. doi:10.1006/jmbi.1997.1234.
11. Lo Conte L, Chothia C, Janin J. The atomic structure of protein-protein recognition sites. J Mol Biol (1999) 285:2177-98. doi:10.1006/jmbi.1998.2439.
12. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. J Mol Biol (1998) 280:1-9. doi:10.1006/jmbi.1998.1843.
13. Chakrabarti P, Janin J. Dissecting protein-protein recognition sites. Proteins (2002) 47:334-43. doi:10.1002/prot.10085.
14. Keskin O. Binding induced conformational changes of proteins correlate with their intrinsic fluctuations: a case study of antibodies. BMC Struct Biol (2007) 7:31. doi:10.1186/1472-6807-7-31.
15. McCoy AJ, Chandana Epa V, Colman PM. Electrostatic complementarity at protein/protein interfaces. J Mol Biol (1997) 268:570-84. doi:10.1006/jmbi.1997.0987.
16. Neuvirth H, Raz R, Schreiber G. ProMate: a structure based prediction program to identify the location of protein-protein binding sites. J Mol Biol (2004) 338:181-99. doi:10.1016/j.jmb.2004.02.040.
17. Ma B, Elkayam T, Wolfson H, Nussinov R. Protein-protein interactions: structurally conserved residues distinguish between binding sites and exposed protein surfaces. Proc Natl Acad Sci U S A (2003) 100:5772-7. doi:10.1073/pnas.1030237100.
18. Bordner AJ, Abagyan R. Statistical analysis and prediction of protein-protein interfaces. Proteins (2005) 60:353-66. doi:10.1002/prot.20433.
19. Ofran Y, Rost B. Analysing six types of protein-protein interfaces. J Mol Biol (2003) 325:377-87. doi:10.1016/S0022-2836(02)01223-8.
20. Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, Winter G. By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (N Y) (1992) 10:779-83. doi:10.1038/nbt0792-779.
21. Soderlind E, Ohlin M, Carlsson R. Complementarity-determining region (CDR) implantation: a theme of recombination. Immunotechnology (1999) 4:279-85.
22. Hemminki A, Niemi S, Hautoniemi L, Soderlund H, Takkinen K. Fine tuning of an anti-testosterone antibody binding site by stepwise optimisation of the CDRs. Immunotechnology (1998) 4:59-69. doi:10.1016/S1380-2933(98)00002-5.
23. Ohlin M, Owman H, Mach M, Borrebaeck CA. Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Mol Immunol (1996) 33:47-56. doi:10.1016/0161-5890(95)00123-9.
24. Mirick GR, Bradt BM, Denardo SJ, Denardo GL. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging (2004) 48:251-7.
25. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (1986) 321:522-5. doi:10.1038/321522a0.
26. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A (1989) 86:10029-33. doi:10.1073/pnas.86.24.10029.
27. Co MS, Queen C. Humanized antibodies for therapy. Nature (1991) 351:501-2. doi:10.1038/351501a0.
28. Padlan EA, Abergel C, Tipper JP. Identification of specificity-determining residues in antibodies. FASEB J (1995) 9:133-9.
29. Ofran Y, Schlessinger A, Rost B. Automated identification of complementarity determining regions (CDRs) reveals peculiar characteristics of CDRs and B cell epitopes. J Immunol (2008) 181:6230-5.
30. Kunik V, Peters B, Ofran Y. Structural consensus among antibodies defines the antigen binding site. PLoS Comput Biol (2012) 8:e1002388. doi:10.1371/journal.pcbi.1002388.
31. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res (2000) 28:235-42. doi:10.1093/nar/28.1.235.
32. Haidar JN, Yuan QA, Zeng L, Snavely M, Luna X, Zhang H, et al. A universal combinatorial design of antibody framework to graft distinct CDR sequences: a bioinformatics approach. Proteins (2012) 80:896-912. doi:10.1002/prot.23246.
33. Hanf KJ, Arndt JW, Chen LL, Jarpe M, Boriack-Sjodin PA, Li Y, et al. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework. Methods (2013). doi:10.1016/j.ymeth.2013.06.024.
34. Amanna IJ, Slifka MK, Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol Rev (2006) 211:320-37. doi:10.1111/j.0105-2896.2006.00392.x.
35. Yang XD, Yu XL. An introduction to epitope prediction methods and software. Rev Med Virol (2009) 19:77-96. doi:10.1002/rmv.602.
36. Xu XL, Sun J, Liu Q, Wang XJ, Xu TL, Zhu RX, et al. Evaluation of spatial epitope computational tools based on experimentally-confirmed dataset for protein antigens. Chin Sci Bull (2010) 55:2169-74. doi:10.1007/s11434-010-3199-z.
37. Hopp TP, Woods KR. Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci U S A (1981) 78:3824-8. doi:10.1073/pnas.78.6.3824.
38. Ponomarenko JV, Bourne PE. Antibody-protein interactions: benchmark datasets and prediction tools evaluation. BMC Struct Biol (2007) 7:64. doi:10.1186/1472-6807-7-64.
39. Blythe MJ, Flower DR. Benchmarking B cell epitope prediction: underperformance of existing methods. Protein Sci (2005) 14:246-8. doi:10.1110/ps.041059505.
40. Ansari HR, Raghava GP. Identification of conformational B-cell epitopes in an antigen from its primary sequence. Immunome Res (2010) 6:6. doi:10.1186/1745-7580-6-6.
41. Kulkarni-Kale U, Bhosle S, Kolaskar AS. CEP: a conformational epitope prediction server. Nucleic Acids Res (2005) 33:W168-71. doi:10.1093/nar/gki460.
42. Liang SD, Zheng DD, Zhang C, Zacharias M. Prediction of antigenic epitopes on protein surfaces by consensus scoring. BMC Bioinformatics (2009) 10:302. doi:10.1186/1471-2105-10-302.
43. Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A, et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics (2008) 9:514. doi:10.1186/1471-2105-9-514.
44. Rubinstein ND, Mayrose I, Pupko T. A machine-learning approach for predicting B-cell epitopes. Mol Immunol (2009) 46:840-7. doi:10.1016/j.molimm.2008.09.009.
45. Rubinstein ND, Mayrose I, Martz E, Pupko T. Epitopia: a web-server for predicting B-cell epitopes. BMC Bioinformatics (2009) 10:287. doi:10.1186/1471-2105-10-287.
46. Sun J, Wu D, Xu T, Wang X, Xu X, Tao L, et al. SEPPA: a computational server for spatial epitope prediction of protein antigens. Nucleic Acids Res (2009) 37:W612-6. doi:10.1093/nar/gkp417.
47. Sweredoski MJ, Baldi P. PEPITO: improved discontinuous B-cell epitope prediction using multiple distance thresholds and half sphere exposure. Bioinformatics (2008) 24:1459-60. doi:10.1093/bioinformatics/btn199.
48. Ambroise J, Giard J, Gala JL, Macq B. Identification of relevant properties for epitopes detection using a regression model. IEEE/ACM Trans Comput Biol Bioinform (2011) 8:1700-7. doi:10.1109/TCBB.2011.77.
49. Liang S, Zheng D, Standley DM, Yao B, Zacharias M, Zhang C. EPSVR and EPMeta: prediction of antigenic epitopes using support vector regression and multiple server results. BMC Bioinformatics (2010) 11:381. doi:10.1186/1471-2105-11-381.
50. Zhang W, Xiong Y, Zhao M, Zou H, Ye X, Liu J. Prediction of conformational B-cell epitopes from 3D structures by random forests with a distance-based feature. BMC Bioinformatics (2011) 12:10. doi:10.1186/1471-2105-12-341.
51. Janin J, Chothia C. The structure of protein-protein recognition sites. J Biol Chem (1990) 265:16027-30.
52. Kunik V, Ofran Y. The indistinguishability of epitopes from protein surface is explained by the distinct binding preferences of each of the six antigen-binding loops. Protein Eng Des Sel (2013). doi:10.1093/protein/gzt027.
53. Kringelum JV, Nielsen M, Padkjær SB, Lund O. Structural analysis of B-cell epitopes in antibody:protein complexes. Mol Immunol (2013) 53:24-34. doi:10.1016/j.molimm.2012.06.001.
54. Benjamin DC, Berzofsky JA, East IJ, Gurd FR, Hannum C, Leach SJ, et al. The antigenic structure of proteins: a reappraisal. Annu Rev Immunol (1984) 2:67-101. doi:10.1146/annurev.iy.02.040184.000435.
55. Greenbaum JA, Andersen PH, Blythe M, Bui HH, Cachau RE, Crowe J, et al. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit (2007) 20:75-82. doi:10.1002/jmr.815.
56. Novotnỳ J, Handschumacher M, Haber E, Bruccoleri RE, Carlson WB, Fanning DW, et al. Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains). Proc Natl Acad Sci U S A (1986) 83:226-30. doi:10.1073/pnas.83.2.226.
57. Thornton JM, Edwards MS, Taylor WR, Barlow DJ. Location of "continuous" antigenic determinants in the protruding regions of proteins. EMBO J (1986) 5:409-13.
58. Zhao L, Li JY. Mining for the antibody-antigen interacting associations that predict the B cell epitopes. BMC Struct Biol (2010) 10(Suppl 1):S6. doi:10.1186/1472-6807-10-S1-S6.
59. Zhao L, Wong L, Li JY. Antibody-specified b-cell epitope prediction in line with the principle of context-awareness. IEEE/ACM Trans Comput Biol Bioinform (2011) 8:1483-94. doi:10.1109/TCBB.2011.49.
60. Soga S, Kuroda D, Shirai H, Kobori M, Hirayama N. Use of amino acid composition to predict epitope residues of individual antibodies. Protein Eng Des Sel (2010) 23:441-8. doi:10.1093/protein/gzq014.
61. Edelman GM, Benacerraf B. On structural and functional relations between antibodies and proteins of the gamma-system. Proc Natl Acad Sci U S A (1962) 48:1035-42. doi:10.1073/pnas.48.6.1035.
62. Putnam FW, Liu YS, Low TL. Primary structure of a human IgA1 immunoglobulin. IV. Streptococcal IgA1 protease, digestion, Fab and Fc fragments, and the complete amino acid sequence of the alpha 1 heavy chain. J Biol Chem (1979) 254:2865-74.
63. Wu TT, Kabat EA. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med (1970) 132:211-50. doi:10.1084/jem.132.2.211.
64. Kabat EA, Wu TT, Bilofsky H, Reid-Miller M, Perry H. Sequence of Proteins of Immunological Interest. Bethesda: National Institute of Health (1983).
65. Chothia C, Lesk AM. Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol (1987) 196:901-17. doi:10.1016/0022-2836(87)90412-8.
66. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, et al. Conformations of immunoglobulin hypervariable regions. Nature (1989) 342:877-83. doi:10.1038/342877a0.
67. Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol (1997) 273:927-48. doi:10.1006/jmbi.1997.1354.
68. Giudicelli V, Chaume D, Bodmer J, Muller W, Busin C, Marsh S, et al. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res (1997) 25:206-11. doi:10.1093/nar/25.1.206.
69. Lefranc MP, Pommié C, Ruiz M, Giudicelli V, Foulquier E, Truong L, et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol (2003) 27:55-77. doi:10.1016/S0145-305X(02)00039-3.
70. Honegger A, Pluckthun A. Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. J Mol Biol (2001) 309:657-70. doi:10.1006/jmbi.2001.4662.
71. Wang F, Ekiert DC, Ahmad I, Yu W, Zhang Y, Bazirgan O, et al. Reshaping antibody diversity. Cell (2013) 153:1379-93. doi:10.1016/j.cell.2013.04.049.
72. Padlan EA. Anatomy of the antibody molecule. Mol Immunol (1994) 31:169-217. doi:10.1016/0161-5890(94)90001-9.
73. MacCallum RM, Martin AC, Thornton JM. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol (1996) 262:732-45. doi:10.1006/jmbi.1996.0548.
74. Kunik V, Ashkenazi S, Ofran Y. Paratome: an online tool for systematic identification of antigen binding regions in antibodies based on sequence or structure. Nucleic Acids Res (2012) 40(Web Server issue):W521-4. doi:10.1093/nar/gks480.
75. Jones S, Thornton JM. Prediction of protein-protein interaction sites using patch analysis. J Mol Biol (1997) 272:133-43. doi:10.1006/jmbi.1997.1234.
76. Cohen GH, Silverton EW, Padlan EA, Dyda F, Wibbenmeyer JA, Willson RC, et al. Water molecules in the antibody-antigen interface of the structure of the Fab HyHEL-5-lysozyme complex at 1.7 A resolution: comparison with results from isothermal titration calorimetry. Acta Crystallogr D Biol Crystallogr (2005) 61:628-33. doi:10.1107/S0907444905007870.
77. Collis AV, Brouwer AP, Martin AC. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J Mol Biol (2003) 325:337-54. doi:10.1016/S0022-2836(02)01222-6.
78. Raghunathan G, Smart J, Williams J, Almagro J. Antigen-binding site anatomy and somatic mutations in antibodies that recognize different types of antigens. J Mol Recognit (2012) 25:103-13. doi:10.1002/jmr.2158.
79. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol (2009) 27:331-7. doi:10.1038/nbt0409-331.
80. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol (2005) 23:1126-36. doi:10.1038/nbt1142.
81. Hudson PJ, Souriau C. Engineered antibodies. Nat Med (2003) 9:129-34. doi:10.1038/nm0103-129.
82. Jain M, Kamal N, Batra SK. Engineering antibodies for clinical applications. Trends Biotechnol (2007) 25:307-16. doi:10.1016/j.tibtech.2007.05.001.
83. Ward ES, Güssow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature (1989) 341:544-6. doi:10.1038/341544a0.
84. Rinfret A, Horne C, Dorrington KJ, Klein M. Noncovalent association of heavy and light chains of human immunoglobulins. IV. The roles of the CH1 and CL domains in idiotypic expression. J Immunol (1985) 135:2574-81.
85. Berry MJ, Davies J. Use of antibody fragments in immunoaffinity chromatography. Comparison of FV fragments, VH fragments and paralog peptides. J Chromatogr (1992) 597:239-45. doi:10.1016/0021-9673(92)80116-C.
86. Pereira B, Benedict CR, Le A, Shapiro SS, Thiagarajan P. Cardiolipin binding a light chain from lupus-prone mice. Biochemistry (1998) 37:1430-7. doi:10.1021/bi972277q.
87. Dubnovitsky AP, Kravchuk ZI, Chumanevich AA, Cozzi A, Arosio P, Martsev SP. Expression, refolding, and ferritin-binding activity of the isolated VL-domain of monoclonal antibody F11. Biochemistry (Mosc) (2000) 65:1011-8.
88. Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science (1995) 267:383-6. doi:10.1126/science.7529940.
89. Sheinerman FB, Norel R, Honig B. Electrostatic aspects of protein-protein interactions. Curr Opin Struct Biol (2000) 10:153-9. doi:10.1016/S0959-440X(00)00065-8.
90. Ofran Y. Prediction of Protein Interaction Sites. Computational Protein-Protein Interactions R Nussinov and G Schreiber. Boca Raton: CRC Press (2009). p. 167-84.
91. Park BW, Zhang HT, Wu C, Berezov A, Zhang X, Dua R, et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol (2000) 18:194-8. doi:10.1038/72651.
92. Polonelli L, Pontón J, Elguezabal N, Moragues MD, Casoli C, Pilotti E, et al. Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. PLoS One (2008) 3(6):e2371. doi:10.1371/journal.pone.0002371.
93. Kang CY, Brunck TK, Kieber-Emmons T, Blalock JE, Kohler H. Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide. Science (1988) 240:1034-6. doi:10.1126/science.3368787.
94. Taub R, Hsu JC, Garsky VM, Hill BL, Erlanger BF, Kohn LD. Peptide sequences from the hypervariable regions of two monoclonal anti-idiotypic antibodies against the thyrotropin (TSH) receptor are similar to TSH and inhibit TSH-increased cAMP production in FRTL-5 thyroid cells. J Biol Chem (1992) 267:5977-84.
95. Saragovi HU, Fitzpatrick D, Raktabutr A, Nakanishi H, Kahn M, Greene MI. Design and synthesis of a mimetic from an antibody complementarity-determining region. Science (1991) 253:792-5. doi:10.1126/science.1876837.
96. Levi M, Sällberg M, Rudén U, Herlyn D, Maruyama H, Wigzell H, et al. A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci U S A (1993) 90:4374-8. doi:10.1073/pnas.90.10.4374.
97. Tsumoto K, Misawa S, Ohba Y, Ueno T, Hayashi H, Kasai N, et al. Inhibition of hepatitis C virus NS3 protease by peptides derived from complementarity-determining regions (CDRs) of the monoclonal antibody 8D4: tolerance of a CDR peptide to conformational changes of a target. FEBS Lett (2002) 525:77-82. doi:10.1016/S0014-5793(02)03090-9.
98. Feng Y, Chung D, Garrard L, McEnroe G, Lim D, Scardina J, et al. Peptides derived from the complementarity-determining regions of anti-Mac-1 antibodies block intercellular adhesion molecule-1 interaction with Mac-1. J Biol Chem (1998) 273:5625-30. doi:10.1074/jbc.273.10.5625.
99. Feng J, Li Y, Zhang W, Shen B. Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design. Immunol Lett (2005) 98:311-6. doi:10.1016/j.imlet.2004.12.006.
100. Lasonder E, Bloemhoff W, Welling GW. Interaction of lysozyme with synthetic anti-lysozyme D1.3 antibody fragments studied by affinity chromatography and surface plasmon resonance. J Chromatogr A (1994) 676:91-8. doi:10.1016/0021-9673(94)00125-1.
101. Schellekens GA. Molecular Aspects of Antibody-Antigen Interactions: Size Reduction of a Herpes Simplex Virus Neutralizing Antibody and its Antigen. Groningen: University of Groningen (1996).
102. Burkovitz A, Leiderman O, Sela-Culang I, Byk G, Ofran Y. Computational identification of antigen-binding antibody fragments. J Immunol (2013) 190:2327-34. doi:10.4049/jimmunol.1200757.
103. Bourgeois C, Bour JB, Aho LS, Pothier P. Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice. J Virol (1998) 72:807-10.
104. Williams WV, Kieber-Emmons T, VonFeldt J, Greene MI, Weiner DB. Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity. J Biol Chem (1991) 266:5182-90.
105. Barrios Y, Jirholt P, Ohlin M. Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor. J Mol Recognit (2004) 17:332-8. doi:10.1002/jmr.679.
106. Kuroda D, Shirai H, Kobori M, Nakamura H. Structural classification of CDR-H3 revisited: a lesson in antibody modeling. Proteins (2008) 73:608-20. doi:10.1002/prot.22087.
107. Sela-Culang I, Alon S, Ofran Y. A systematic comparison of free and bound antibodies reveals binding-related conformational changes. J Immunol (2012) 189:4890-9. doi:10.4049/jimmunol.1201493.
108. Sedrak P, Hsu K, Mohan C. Molecular signatures of anti-nuclear antibodies-contribution of heavy chain framework residues. Mol Immunol (2003) 40:491-9. doi:10.1016/S0161-5890(03)00223-2.
109. Xiang J, Sha Y, Jia Z, Prasad L, Delbaere L. Framework residue-71 and residue-93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops. J Mol Biol (1995) 253:385-90. doi:10.1006/jmbi.1995.0560.
110. Verhoeyen M, Milstein C, Winter G. Reshaping human antibodies: grafting an antilysozyme activity. Science (1988) 239:1534-6. doi:10.1126/science.2451287.
111. Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng (1991) 4:773-83. doi:10.1093/protein/4.7.773.
112. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A (1992) 89:4285-9. doi:10.1073/pnas.89.10.4285.
113. Baca M, Presta L, O'Connor S, Wells J. Antibody humanization using monovalent phage display. J Biol Chem (1997) 272:10678-84. doi:10.1074/jbc.272.16.10678.
114. Rodríguez-Rodríguez ER, Ledezma-Candanoza LM, Contreras-Ferrat LG, Olamendi-Portugal T, Possani LD, Becerril B, et al. A single mutation in framework 2 of the heavy variable domain improves the properties of a diabody and a related single-chain antibody. J Mol Biol (2012) 423:337-50. doi:10.1016/j.jmb.2012.07.007.
115. Chiu WC, Lai YP, Chou MY. Humanization and characterization of an anti-human TNF-alpha murine monoclonal antibody. PLoS One (2011) 6:e16373. doi:10.1371/journal.pone.0016373.
116. Davies DR, Chacko S. Antibody structure. Acc Chem Res (1993) 26:421-7. doi:10.1021/ar00032a005.
117. Schroeder H, Hillson J, Perlmutter R. Structure and evolution of mammalian VH families. Int Immunol (1990) 2:41-50. doi:10.1093/intimm/2.1.41.
118. Amit A, Mariuzza R, Phillips S, Poljak R. 3-Dimensional structure of an antigen-antibody complex at 2.8 a resolution. Science (1986) 233:747-53. doi:10.1126/science.2426778.
119. Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol (1992) 224:487-99. doi:10.1016/0022-2836(92)91010-M.
120. Tramontano A, Chothia C, Lesk A. Framework residue-71 is a major determinant of the position and conformation of the 2nd hypervariable region in the VH domains of immunoglobulins. J Mol Biol (1990) 215:175-82. doi:10.1016/S0022-2836(05)80102-0.
121. Holmes M, Buss T, Foote J. Structural effects of framework mutations on a humanized anti-lysozyme antibody. J Immunol (2001) 167:296-301.
122. Potter K, Hobby P, Klijn S, Stevenson F, Sutton B. Evidence for involvement of a hydrophobic patch in framework region 1 of human v4-34-encoded igs in recognition of the red blood cell I antigen. J Immunol (2002) 169:3777-82.
123. Pospisil R, Youngcooper G, Mage R. Preferential expansion and survival of B-lymphocytes based on VH framework-1 and framework-3 expression: "positive" selection in appendix of normal and VH-mutant rabbits. Proc Natl Acad Sci USA (1995) 92:6961-5. doi:10.1073/pnas.92.15.6961.
124. Capra J, Kehoe J. Variable region sequences of 5 human immunoglobulin heavy chains of VH3 subgroup: definitive identification of four heavy chain hypervariable regions. Proc Natl Acad Sci USA (1974) 71:845-8. doi:10.1073/pnas.71.3.845.
125. Banfield M, King D, Mountain A, Brady R. V-L:V-H domain rotations in engineered antibodies: crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs. Proteins (1997) 29:161-71. doi:10.1002/(SICI)1097-0134(199710)29:2<161::AID-PROT4>3.0.CO;2-G.
126. Nakanishi T, Tsumoto K, Yokota A, Kondo H, Kumagai I. Critical contribution of VH-VL interaction to reshaping of an antibody: the case of humanization of anti-lysozyme antibody, HyHEL-10. Protein Sci (2008) 17:261-70. doi:10.1110/ps.073156708.
127. Stanfield R, Takimotokamimura M, Rini J, Profy A, Wilson I. Major antigen-induced domain rearrangements in an antibody. Structure (1993) 1:83-93. doi:10.1016/0969-2126(93)90024-B.
128. Tan P, Sandmaier B, Stayton P. Contributions of a highly conserved VHNL hydrogen bonding interaction to scFv folding stability and refolding efficiency. Biophys J (1998) 75:1473-82. doi:10.1016/S0006-3495(98)74066-4.
129. Essen L, Skerra A. The de-novo design of an antibody combining site-crystallographic analysis of the V-L domain confirms the structural model. J Mol Biol (1994) 238:226-44. doi:10.1006/jmbi.1994.1284.
130. Masuda K, Sakamoto K, Kojima M, Aburatani T, Ueda T, Ueda H. The role of interface framework residues in determining antibody V-H/V-L interaction strength and antigen-binding affinity. Febs J (2006) 273:2184-94. doi:10.1111/j.1742-4658.2006.05232.x.
131. Torres M, Casadevall A. The immunoglobulin constant region contributes to affinity and specificity. Trends Immunol (2008) 29: 91-7. doi:10.1016/j.it.2007.11.004.
132. Casadevall A, Janda A. Immunoglobulin isotype influences affinity and specificity. Proc Natl Acad Sci U S A (2012) 109:12272-3. doi:10.1073/pnas.1209750109.
133. Janda A, Casadevall A. Circular dichroism reveals evidence of coupling between immunoglobulin constant and variable region secondary structure. Mol Immunol (2010) 47:1421-5. doi:10.1016/j.molimm.2010.02.018.
134. Dam TK, Torres M, Brewer CF, Casadevall A. Isothermal titration calorimetry reveals differential binding thermodynamics of variable region-identical antibodies differing in constant region for a univalent ligand. J Biol Chem (2008) 283:31366-70. doi:10.1074/jbc.M806473200.
135. Pritsch O, Hudry-Clergeon G, Buckle M, Petillot Y, Bouvet JP, Gagnon J, et al. Can immunoglobulin C(H)1 constant region domain modulate antigen binding affinity of antibodies? J Clin Invest (1996) 98:2235-43. doi:10.1172/JCI119033.
136. Pritsch O, Magnac C, Dumas G, Bouvet JP, Alzari P, Dighiero G. Can isotype switch modulate antigen-binding affinity and influence clonal selection? Eur J Immunol (2000) 30(12):3387-95. doi:10.1002/1521-4141(2000012)30:12<3387::AID-IMMU3387>3.0.CO;2-K.
137. Torres M, May R, Scharff MD, Casadevall A. Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J Immunol (2005) 174:2132-42.
138. Torres M, Fernández-Fuentes N, Fiser A, Casadevall A. The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem (2007) 282:13917-27. doi:10.1074/jbc.M700661200.
139. McLean GR, Torres M, Elguezabal N, Nakouzi A, Casadevall A. Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J Immunol (2002) 169:1379-86.
140. Cooper LJ, Shikhman AR, Glass DD, Kangisser D, Cunningham MW, Greenspan NS. Role of heavy chain constant domains in antibody-antigen interaction. Apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains. J Immunol (1993) 150:2231-42.
141. McCloskey N, Turner MW, Steffner P, Owens R, Goldblatt D. Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses. Immunology (1996) 88:169-73. doi:10.1111/j.1365-2567.1996.tb00001.x.
142. Michaelsen TE, Ihle Ø, Beckstrøm KJ, Herstad TK, Sandin RH, Kolberg J, et al. Binding properties and anti-bacterial activities of V-region identical, human IgG and IgM antibodies, against group B Neisseria meningitidis. Biochem Soc Trans (2003) 31:1032-5. doi:10.1042/BST0311032.
143. Liu F, Bergami PL, Duval M, Kuhrt D, Posner M, Cavacini L. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120. AIDS Res Hum Retroviruses (2003) 19:597-607. doi:10.1089/088922203322230969.
144. Tudor D, Yu H, Maupetit J, Drillet AS, Bouceba T, Schwartz-Cornil I, et al. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proc Natl Acad Sci U S A (2012) 109:12680-5. doi:10.1073/pnas.1200024109.
145. Torosantucci A, Chiani P, Bromuro C, De Bernardis F, Palma AS, Liu Y, et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One (2009) 4:e5392. doi:10.1371/journal.pone.0005392.
146. Xia Y, Janda A, Eryilmaz E, Casadevall A, Putterman C. The constant region affects antigen binding of antibodies to DNA by altering secondary structure. Mol Immunol (2013) 56:28-37. doi:10.1016/j.molimm.2013.04.004.
147. Adachi M, Kurihara Y, Nojima H, Takeda-Shitaka M, Kamiya K, Umeyama H. Interaction between the antigen and antibody is controlled by the constant domains: normal mode dynamics of the HEL-HyHEL-10 complex. Protein Sci (2003) 12:2125-31. doi:10.1110/ps.03100803.
148. Xia Y, Pawar RD, Nakouzi AS, Herlitz L, Broder A, Liu K, et al. The constant region contributes to the antigenic specificity and renal pathogenicity of murine anti-DNA antibodies. J Autoimmun (2012) 39:398-411. doi:10.1016/j.jaut.2012.06.005.
149. Oda M, Kozono H, Morii H, Azuma T. Evidence of allosteric conformational changes in the antibody constant region upon antigen binding. Int Immunol (2003) 15:417-26. doi:10.1093/intimm/dxg036.
150. Piekarska B, Drozd A, Konieczny L, Król M, Jurkowski W, Roterman I, et al. The indirect generation of long-distance structural changes in antibodies upon their binding to antigen. Chem Biol Drug Des (2006) 68:276-83. doi:10.1111/j.1747-0285.2006.00448.x.
151. Horgan C, Brown K, Pincus SH. Effect of H-chain V-region on complement activation by immobilized immune-complexes. J Immunol (1992) 149:127-35.
152. Vidarte L, Pastor C, Mas S, Blazquez AB, de los Rios V, Guerrero R, et al. Serine 132 is the C3 covalent attachment point on the CH1 domain of human IgG1. J Biol Chem (2001) 276(41): 38217-23.
153. Braden BC, Poljak RJ. Structural features of the reactions-between antibodies and protein antigens. FASEB J (1995) 9:9-16.
154. Pellequer JL, Chen SW, Roberts VA, Tainer JA, Getzoff ED. Unraveling the effect of changes in conformation and compactness at the antibody V-L-V-H interface upon antigen binding. J Mol Recog (1999) 12:267-75. doi:10.1002/(SICI)1099-1352(199907/08)12:4<267::AID-JMR465>3.3.CO;2-0.
155. Wilson IA, Stanfield RL. Antibody-antigen interactions-new structures and new conformational-changes. Curr Opin Struct Biol (1994) 4:857-67. doi:10.1016/0959-440X(94)90267-4.